Abstract 202P
Background
Tumor-infiltrating B cells (TIB) and especially B cells organized in tertiary lymphoid structures (TLS) correlate with better prognosis in lung cancer patients. B cells in the TLS were found to express typical markers of late-stage maturation, somatic hypermutation and class switch recombination of immunoglobulin genes, indicating a cancer-driven clonal expansion. In some cases, research showed that secreted immunoglobulins of the repertoire were having a direct tumor killing activity.
Methods
To decipher and then harness the potential of these tumor-trained antibodies, we analyze recombinant cognate repertoires of tumor infiltrating B cells from lung cancer surgical resections. We leverage the capabilities of Dropzylla®, a cutting-edge single-cell microfluidic platform, to extract and clone the comprehensive B cell antibody repertoire from up to a million tumor-derived B cells. The recombinant antibody repertoires are then screened in a panel of assays designed to identify antibodies with anti-tumor properties. For instance, identification of antibodies showing specific binding to cancer cells. Once identified, the monoclonal antibody is then used to deconvolute novel tumor associated antigens.
Results
The antibodies obtained from lung cancer resections bearing TLS were analyzed by next generation sequencing (NGS). It revealed that a typical sample of approximately one cubic centimeter of tumor tissue yielded thousands of antibody families. The sequences show signs of affinity maturation and clonal expansion which may indicate an antigen-driven B cell development induced by the tumor microenvironment. Some of the tumor derived monoclonal antibodies do bind to cancer cell lines but not healthy cells. Some show direct tumor cell growth inhibition and others promote NK cell mediated killing of cancer cells.
Conclusions
Tumor derived antibodies can bind to shared tumor associated antigens and can have direct anti-tumor activities. We are currently evaluating the targets of the antibodies. These promising results may lead us to discover novel pathways to be exploited as therapy and contribute to further understanding B cells biology in cancer.
Legal entity responsible for the study
Memo Therapeutics AG.
Funding
Memo Therapeutics AG.
Disclosure
M. Delince: Financial Interests, Personal, Full or part-time Employment: Memo Therapeutics AG.
Resources from the same session
109P - Efficacy of first-line immune-based combined systemic therapy and brain radiotherapy in patients with brain metastases (BM) from driver gene-negative NSCLC
Presenter: Mengxing You
Session: Poster Display session
110P - Safety and effectiveness of adebrelimab as first-line treatment in extensive-stage small-cell lung cancer: A prospective, real-world study
Presenter: Junxu Wen
Session: Poster Display session
111P - Real-world treatment patterns and clinical outcomes in Chinese stage III non-small cell lung cancer (NSCLC) patients: Results of MOOREA study
Presenter: Ligang Xing
Session: Poster Display session
112P - Serplulimab combined with chemotherapy and anlotinib for extensive-stage small-cell lung cancer: A multicenter real-world experience
Presenter: Jun Wang
Session: Poster Display session
113P - Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: An observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study)
Presenter: Irene Torresan
Session: Poster Display session
115P - Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors in Germany: A population-based study
Presenter: Lucie Heinzerling
Session: Poster Display session
116TiP - An umbrella trial (RECHALLENGE) to evaluate the safety and preliminary efficacy of combination or sequential immunotherapy in advanced solid tumor patients after disease progression in clinical trials
Presenter: Huilei Miao
Session: Poster Display session
122P - Intracellular adenosine drives profound lymphocyte suppression and can be reversed with EOS-984: A potent ENT1 antagonist
Presenter: Erica Houthuys
Session: Poster Display session
123P - Combination potential of EO-3021, a CLDN18.2 vc-MMAE ADC, with VEGFR2 or PD1 inhibition in preclinical models of CLDN18.2-expressing cancers
Presenter: Thomas O'Hare
Session: Poster Display session